Literature DB >> 16990006

Synthesis and evaluation of a classical 2,4-diamino-5-substituted-furo[2,3-d]pyrimidine and a 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidine as antifolates.

Aleem Gangjee1, Jie Yang, John J McGuire, Roy L Kisliuk.   

Abstract

Two classical antifolates, a 2,4-diamino-5-substituted furo[2,3-d]pyrimidine and a 2-amino-4-oxo-6-substituted pyrrolo[2,3-d]pyrimidine, were synthesized as potential inhibitors of dihydrofolate reductase (DHFR) and thymidylate synthase (TS). The syntheses were accomplished by condensation of 2,6-diamino-3(H)-4-oxo-pyrimidine with alpha-chloro-ketone 21 to afford two key intermediates 23 and 24, followed by hydrolysis, coupling with l-glutamate diethyl ester and saponification of the diethyl ester to afford the classical antifolates 13 and 14. Compounds 13 and 14 with a single carbon atom bridge are both substrates for folylpoly-gamma-glutamate synthetase (FPGS), the enzyme responsible for forming critical poly-gamma-glutamate antifolate metabolites with increased potency and/or increased cell retention. Compound 14 is a highly efficient FPGS substrate demonstrating that 2,4-diamino-5-substituted furo[2,3-d]pyrimidines are important lead structures for the design of antifolates with FPGS substrate activity. It retains inhibitory potency for DHFR and TS compared to the two atom bridged analog 5. Compound 13 is a poor inhibitor of purified DHFR and TS, and both 13 and 14 are poor inhibitors of the growth of CCRF-CEM human leukemia cells in culture, indicating that single carbon bridged compounds in these series though conducive to FPGS substrate activity were not potent inhibitors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16990006      PMCID: PMC3850758          DOI: 10.1016/j.bmc.2006.08.029

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  25 in total

Review 1.  Chemistry and biological activity of antifolates.

Authors:  A Rosowsky
Journal:  Prog Med Chem       Date:  1989

2.  Molecular and karyological analysis of methotrexate-resistant and -sensitive human leukemic CCRF-CEM cells.

Authors:  E Mini; S Srimatkandada; W D Medina; B A Moroson; M D Carman; J R Bertino
Journal:  Cancer Res       Date:  1985-01       Impact factor: 12.701

3.  Preparation of 7-oxaaporphine derivatives and evaluation of their dopaminergic activity.

Authors:  C Banzatti; N Carfagna; R Commisso; F Heidempergher; L Pegrassi; P Melloni
Journal:  J Med Chem       Date:  1988-07       Impact factor: 7.446

4.  Effects of methotrexate esters and other lipophilic antifolates on methotrexate-resistant human leukemic lymphoblasts.

Authors:  A Rosowsky; H Lazarus; G C Yuan; W R Beltz; L Mangini; H T Abelson; E J Modest; E Frei
Journal:  Biochem Pharmacol       Date:  1980-02-15       Impact factor: 5.858

5.  Effect of C9-methyl substitution and C8-C9 conformational restriction on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines.

Authors:  A Gangjee; Y Zeng; J J McGuire; R L Kisliuk
Journal:  J Med Chem       Date:  2000-08-10       Impact factor: 7.446

6.  Pyrrolo[2,3-d]pyrimidine thymidylate synthase inhibitors: design and synthesis of one-carbon bridge derivatives.

Authors:  K Aso; Y Imai; K Yukishige; K Ootsu; H Akimoto
Journal:  Chem Pharm Bull (Tokyo)       Date:  2001-10       Impact factor: 1.645

7.  Design, synthesis, and biological activities of classical N-[4-[2-(2-amino-4-ethylpyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and its 6-methyl derivative as potential dual inhibitors of thymidylate synthase and dihydrofolate reductase and as potential antitumor agents.

Authors:  Aleem Gangjee; Jianming Yu; Roy L Kisliuk; William H Haile; Giulia Sobrero; John J McGuire
Journal:  J Med Chem       Date:  2003-02-13       Impact factor: 7.446

Review 8.  Structure, dynamics, and catalytic function of dihydrofolate reductase.

Authors:  Jason R Schnell; H Jane Dyson; Peter E Wright
Journal:  Annu Rev Biophys Biomol Struct       Date:  2004

9.  Antiangiogenic and antitumor agents. Design, synthesis, and evaluation of novel 2-amino-4-(3-bromoanilino)-6-benzylsubstituted pyrrolo[2,3-d]pyrimidines as inhibitors of receptor tyrosine kinases.

Authors:  Aleem Gangjee; Jie Yang; Michael A Ihnat; Shekhar Kamat
Journal:  Bioorg Med Chem       Date:  2003-11-17       Impact factor: 3.641

Review 10.  From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.

Authors:  Jackie Walling
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.651

View more
  5 in total

1.  Efficient one-pot synthesis of novel and diverse furo[2,3-d] pyrimidinediones and thioxofuro[2,3-d] pyrimidineones by the rhodium (II) pivalate-catalyzed reactions of cyclic diazo compounds.

Authors:  Krishna Bahadur Somai Magar; Yong Rok Lee; Sung Hong Kim
Journal:  Mol Divers       Date:  2013-08-02       Impact factor: 2.943

2.  Ethyl 3-(4-fluoro-phen-yl)-6-methyl-4-oxo-2-(1-cyclohexylamino)-3,4-dihydro-furo[2,3-d]pyrimidine-5-carboxyl-ate.

Authors:  Yong Sun; Guo-Ping Zeng; Yang-Gen Hu
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2007-12-21

3.  In silico analysis of the amido phosphoribosyltransferase inhibition by PY873, PY899 and a derivative of isophthalic acid.

Authors:  Sidra Batool; Muhammad Sulaman Nawaz; Mohammad A Kamal
Journal:  Invest New Drugs       Date:  2013-03-13       Impact factor: 3.850

4.  Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.

Authors:  Yijun Deng; Yiqiang Wang; Christina Cherian; Zhanjun Hou; Steven A Buck; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2008-08-05       Impact factor: 7.446

5.  Crystal structures of 2-[(4,6-di-amino-pyrimidin-2-yl)sulfan-yl]-N-(3-nitro-phen-yl)acetamide monohydrate and N-(2-chloro-phen-yl)-2-[(4,6-di-amino-pyrimidin-2-yl)sulfan-yl]acetamide.

Authors:  S Subasri; Ajay Kumar Timiri; Nayan Sinha Barji; Venkatesan Jayaprakash; Viswanathan Vijayan; Devadasan Velmurugan
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2016-07-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.